ケタミン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ケタミン" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

low place

low place

4jamanetwork.com

2,650^th place

3,384^th place

234^th place

363^rd place

102^nd place

78^th place

1natureasia.com

low place

2,077^th place

low place

low place

1bloomberg.co.jp

4,571^st place

282^nd place

2,769^th place

4,586^th place

1oxfordjournals.org

1,389^th place

1,710^th place

1annemergmed.com

low place

low place

1medicallibrary-dsc.info

low place

low place

1,989^th place

4,341^st place

1scienceblog.co.uk

low place

low place

1kyorin-u.ac.jp

low place

7,548^th place

274^th place

596^th place

99^th place

542^nd place

447^th place

1,043^rd place

211^th place

13^th place

1web.archive.org

1^st place

1^st place

low place

low place

1pharmaceutical-journal.com

low place

low place

1reftag.appspot.com

low place

low place

low place

low place

2,393^rd place

4,709^th place

1saitama-np.co.jp

low place

844^th place

annemergmed.com

Green SM, et al. (2011). “Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update”. en:Annals of Emergency Medicine. 57 (5): 449-61. doi:10.1016/j.annemergmed.2010.11.030. PMID 21256625.

bloomberg.co.jp

“Ｊ＆ＪのエスケタミンをＦＤＡ承認－重度うつ病に即効性の治療選択肢”. ブルームバーグ. (2019年3月6日)

bloomberg.com

“First Big Depression Advance Since Prozac Nears FDA Approval.”. Bloomberg News (2019年2月12日). 2019年2月12日閲覧。

doi.org

Hijazi, Y; Boulieu, R (July 2002). “Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes”. Drug Metabolism and Disposition 30 (7): 853–8. doi:10.1124/dmd.30.7.853. PMID 12065445.
Zarate, Carlos A.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K. (2006). “A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression”. Archives of General Psychiatry 63 (8): 856. doi:10.1001/archpsyc.63.8.856. PMID 16894061.
Wilkinson ST, Ballard ED, Bloch MH, et al. (February 2018). “The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis”. Am J Psychiatry (2): 150–158. doi:10.1176/appi.ajp.2017.17040472. PMID 28969441.
Sara Reardon、(翻訳)船田晶子「うつ病治療薬として臨床試験が進むケタミン」（pdf）『Natureダイジェスト』第12巻第4号、2015年、doi:10.1038/ndigest.2015.150414。
Orser BA, et al. (1997). “Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors.”. Anesthesiology. 86 (4): 903-17. doi:10.1097/00000542-199704000-00021. PMID 9105235.
Hirota K, et al. (1996-10). “Ketamine: Its mechanism(s) of action and unusual clinical uses”. en:British Journal of Anaesthesia. 77 (4): 441-4. doi:10.1093/bja/77.4.441. PMID 8942324.
Seeman P, Ko F, Tallerico T. (2005-9). “Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics.”. en:Molecular Psychiatry. 10 (9): 877-83. doi:10.1038/sj.mp.4001682. PMID 15852061.
Green SM, et al. (2011). “Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update”. en:Annals of Emergency Medicine. 57 (5): 449-61. doi:10.1016/j.annemergmed.2010.11.030. PMID 21256625.
Morgan CJA, et al. (2009). “Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study.”. Addiction. 105 (1): 121-33. doi:10.1111/j.1360-0443.2009.02761.x. PMID 19919593.
Patel P. (2009-4). “Update on neonatal anesthetic neurotoxicity: Insight into molecular mechanisms and relevance to humans”. Anesthesiology. 110 (4): 703-8. doi:10.1097/ALN.0b013e31819c42a4. PMC 2737718. PMID 19276968.
Nutt, David (2014). “Help luck along to find psychiatric medicines”. Nature 515 (7526): 165–165. doi:10.1038/515165a. PMID 25391924.
Insel, T. R. (October 2012). “Next-Generation Treatments for Mental Disorders”. Science Translational Medicine 4 (155): 155ps19–155ps19. doi:10.1126/scitranslmed.3004873. PMID 23052292.
図1 は以下に含まれる。Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012-6). “Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial”. Biol Psychiatry 71 (11): 939–46. doi:10.1016/j.biopsych.2011.12.010. PMC 3343177. PMID 22297150.
Grunebaum, Michael F.; Galfalvy, Hanga C.; Choo, Tse-Hwei; et al. (2017). “Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial”. American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17060647. PMID 29202655.
Diazgranados, Nancy; Ibrahim, Lobna; Brutsche, Nancy E.; Newberg, Andrew; Kronstein, Phillip; Khalife, Sami; Kammerer, William A.; Quezado, Zenaide et al. (2010). “A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression”. Archives of General Psychiatry 67 (8): 793. doi:10.1001/archgenpsychiatry.2010.90. PMC 3000408. PMID 20679587.
Feder, Adriana; Parides, Michael K.; Murrough, James W.; Perez, Andrew M.; Morgan, Julia E.; Saxena, Shireen; Kirkwood, Katherine; aan het Rot, Marije et al. (2014). “Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder”. JAMA Psychiatry 71 (6): 681. doi:10.1001/jamapsychiatry.2014.62. PMID 24740528.
Rodriguez, Carolyn I; Kegeles, Lawrence S; Levinson, Amanda; Feng, Tianshu; Marcus, Sue M; Vermes, Donna; Flood, Pamela; Simpson, Helen B (2013). “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept”. Neuropsychopharmacology 38 (12): 2475–2483. doi:10.1038/npp.2013.150. PMC 3799067. PMID 23783065.
Taylor, Jerome H; Landeros-Weisenberger, Angeli; Coughlin, Catherine; et al. (2017). [10.1038/npp.2017.194 “Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial”]. Neuropsychopharmacology 43 (2): 325–333. doi:10.1038/npp.2017.194. PMID 28849779. 10.1038/npp.2017.194.
Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE (2018). “Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review”. Front Psychiatry: 277. doi:10.3389/fpsyt.2018.00277. PMC 6094990. PMID 30140240.
“Side-effects associated with ketamine use in depression: a systematic review”. Lancet Psychiatry 5 (1): 65–78. (2018). doi:10.1016/S2215-0366(17)30272-9. PMID 28757132.
Krystal JH, et al. (1994-3). “Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.”. en:JAMA Psychiatry. 51 (3): 199-214. doi:10.1001/archpsyc.1994.03950030035004. PMID 8122957.

eleusis.us

この研究は先のシステマティックレビュー（PMID30140240）に含まれていない： E. M. Krupitsky et al. "The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment: The Affective Contra-Attribution Method" Alcoholism Treatment Quarterly 9(1), 1992

fda.gov

Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee (2019年2月12日). “FDA Briefing Document”. Food and Drug Administration. 2019年2月12日閲覧。 “Meeting, February 12, 2019. Agenda Topic: The committees will discuss the efficacy, safety, and risk-benefit profile of New Drug Application (NDA) 211243, esketamine 28 mg single-use nasal spray device, submitted by Janssen Pharmaceutica, for the treatment of treatment-resistant depression.”

handle.net

hdl.handle.net

世界保健機関 (2012). WHO Expert Committee on Drug Dependence: thirty-fifth report / WHO Technical Report Series 973 (Report). World Health Organization. pp. 8–9. ISBN 978-92-4-120973-1。

jamanetwork.com

archpsyc.jamanetwork.com

Zarate, Carlos A.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K. (2006). “A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression”. Archives of General Psychiatry 63 (8): 856. doi:10.1001/archpsyc.63.8.856. PMID 16894061.
Diazgranados, Nancy; Ibrahim, Lobna; Brutsche, Nancy E.; Newberg, Andrew; Kronstein, Phillip; Khalife, Sami; Kammerer, William A.; Quezado, Zenaide et al. (2010). “A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression”. Archives of General Psychiatry 67 (8): 793. doi:10.1001/archgenpsychiatry.2010.90. PMC 3000408. PMID 20679587.
Feder, Adriana; Parides, Michael K.; Murrough, James W.; Perez, Andrew M.; Morgan, Julia E.; Saxena, Shireen; Kirkwood, Katherine; aan het Rot, Marije et al. (2014). “Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder”. JAMA Psychiatry 71 (6): 681. doi:10.1001/jamapsychiatry.2014.62. PMID 24740528.

jamanetwork.com

Krystal JH, et al. (1994-3). “Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.”. en:JAMA Psychiatry. 51 (3): 199-214. doi:10.1001/archpsyc.1994.03950030035004. PMID 8122957.

kyorin-u.ac.jp

“杏林大学医学部付属病院 KYORIN UNIVERSITY HOSPITAL”. 杏林大学医学部付属病院　KYORIN UNIVERSITY HOSPITAL. 2023年8月13日閲覧。

lww.com

journals.lww.com

Orser BA, et al. (1997). “Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors.”. Anesthesiology. 86 (4): 903-17. doi:10.1097/00000542-199704000-00021. PMID 9105235.

medicallibrary-dsc.info

“医薬品インタビューフォーム（2012年6月改訂第9版）ケタラール” (pdf). 第一三共株式会社 (2012年6月). 2016年7月28日閲覧。

nature.com

Seeman P, Ko F, Tallerico T. (2005-9). “Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics.”. en:Molecular Psychiatry. 10 (9): 877-83. doi:10.1038/sj.mp.4001682. PMID 15852061.
Nutt, David (2014). “Help luck along to find psychiatric medicines”. Nature 515 (7526): 165–165. doi:10.1038/515165a. PMID 25391924.
Rodriguez, Carolyn I; Kegeles, Lawrence S; Levinson, Amanda; Feng, Tianshu; Marcus, Sue M; Vermes, Donna; Flood, Pamela; Simpson, Helen B (2013). “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept”. Neuropsychopharmacology 38 (12): 2475–2483. doi:10.1038/npp.2013.150. PMC 3799067. PMID 23783065.

natureasia.com

Sara Reardon、(翻訳)船田晶子「うつ病治療薬として臨床試験が進むケタミン」（pdf）『Natureダイジェスト』第12巻第4号、2015年、doi:10.1038/ndigest.2015.150414。

nhs.uk

“Ketamine tested as severe depression treatment”. NHS Choices 2015年11月1日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Hijazi, Y; Boulieu, R (July 2002). “Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes”. Drug Metabolism and Disposition 30 (7): 853–8. doi:10.1124/dmd.30.7.853. PMID 12065445.
Zarate, Carlos A.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K. (2006). “A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression”. Archives of General Psychiatry 63 (8): 856. doi:10.1001/archpsyc.63.8.856. PMID 16894061.
Wilkinson ST, Ballard ED, Bloch MH, et al. (February 2018). “The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis”. Am J Psychiatry (2): 150–158. doi:10.1176/appi.ajp.2017.17040472. PMID 28969441.
Orser BA, et al. (1997). “Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors.”. Anesthesiology. 86 (4): 903-17. doi:10.1097/00000542-199704000-00021. PMID 9105235.
Hirota K, et al. (1996-10). “Ketamine: Its mechanism(s) of action and unusual clinical uses”. en:British Journal of Anaesthesia. 77 (4): 441-4. doi:10.1093/bja/77.4.441. PMID 8942324.
Seeman P, Ko F, Tallerico T. (2005-9). “Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics.”. en:Molecular Psychiatry. 10 (9): 877-83. doi:10.1038/sj.mp.4001682. PMID 15852061.
M.Nishimura, K.Sato et al."Ketamine Inhibits Monoamine transporters expressed in Human Embryonic Kidney 293 cells" Anesthesiology 1998; 88:768-774 PMID 9523822
Green SM, et al. (2011). “Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update”. en:Annals of Emergency Medicine. 57 (5): 449-61. doi:10.1016/j.annemergmed.2010.11.030. PMID 21256625.
Morgan CJA, et al. (2009). “Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study.”. Addiction. 105 (1): 121-33. doi:10.1111/j.1360-0443.2009.02761.x. PMID 19919593.
Patel P. (2009-4). “Update on neonatal anesthetic neurotoxicity: Insight into molecular mechanisms and relevance to humans”. Anesthesiology. 110 (4): 703-8. doi:10.1097/ALN.0b013e31819c42a4. PMC 2737718. PMID 19276968.
Nutt, David (2014). “Help luck along to find psychiatric medicines”. Nature 515 (7526): 165–165. doi:10.1038/515165a. PMID 25391924.
Insel, T. R. (October 2012). “Next-Generation Treatments for Mental Disorders”. Science Translational Medicine 4 (155): 155ps19–155ps19. doi:10.1126/scitranslmed.3004873. PMID 23052292.
図1 は以下に含まれる。Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012-6). “Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial”. Biol Psychiatry 71 (11): 939–46. doi:10.1016/j.biopsych.2011.12.010. PMC 3343177. PMID 22297150.
Grunebaum, Michael F.; Galfalvy, Hanga C.; Choo, Tse-Hwei; et al. (2017). “Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial”. American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17060647. PMID 29202655.
Diazgranados, Nancy; Ibrahim, Lobna; Brutsche, Nancy E.; Newberg, Andrew; Kronstein, Phillip; Khalife, Sami; Kammerer, William A.; Quezado, Zenaide et al. (2010). “A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression”. Archives of General Psychiatry 67 (8): 793. doi:10.1001/archgenpsychiatry.2010.90. PMC 3000408. PMID 20679587.
Feder, Adriana; Parides, Michael K.; Murrough, James W.; Perez, Andrew M.; Morgan, Julia E.; Saxena, Shireen; Kirkwood, Katherine; aan het Rot, Marije et al. (2014). “Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder”. JAMA Psychiatry 71 (6): 681. doi:10.1001/jamapsychiatry.2014.62. PMID 24740528.
Rodriguez, Carolyn I; Kegeles, Lawrence S; Levinson, Amanda; Feng, Tianshu; Marcus, Sue M; Vermes, Donna; Flood, Pamela; Simpson, Helen B (2013). “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept”. Neuropsychopharmacology 38 (12): 2475–2483. doi:10.1038/npp.2013.150. PMC 3799067. PMID 23783065.
Taylor, Jerome H; Landeros-Weisenberger, Angeli; Coughlin, Catherine; et al. (2017). [10.1038/npp.2017.194 “Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial”]. Neuropsychopharmacology 43 (2): 325–333. doi:10.1038/npp.2017.194. PMID 28849779. 10.1038/npp.2017.194.
Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE (2018). “Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review”. Front Psychiatry: 277. doi:10.3389/fpsyt.2018.00277. PMC 6094990. PMID 30140240.
“Side-effects associated with ketamine use in depression: a systematic review”. Lancet Psychiatry 5 (1): 65–78. (2018). doi:10.1016/S2215-0366(17)30272-9. PMID 28757132.
Krystal JH, et al. (1994-3). “Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.”. en:JAMA Psychiatry. 51 (3): 199-214. doi:10.1001/archpsyc.1994.03950030035004. PMID 8122957.

ncbi.nlm.nih.gov

In Vogue: Ketamine for Neuroprotection in Acute Neurologic Injury. (2017)
Patel P. (2009-4). “Update on neonatal anesthetic neurotoxicity: Insight into molecular mechanisms and relevance to humans”. Anesthesiology. 110 (4): 703-8. doi:10.1097/ALN.0b013e31819c42a4. PMC 2737718. PMID 19276968.
図1 は以下に含まれる。Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012-6). “Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial”. Biol Psychiatry 71 (11): 939–46. doi:10.1016/j.biopsych.2011.12.010. PMC 3343177. PMID 22297150.
Diazgranados, Nancy; Ibrahim, Lobna; Brutsche, Nancy E.; Newberg, Andrew; Kronstein, Phillip; Khalife, Sami; Kammerer, William A.; Quezado, Zenaide et al. (2010). “A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression”. Archives of General Psychiatry 67 (8): 793. doi:10.1001/archgenpsychiatry.2010.90. PMC 3000408. PMID 20679587.
Rodriguez, Carolyn I; Kegeles, Lawrence S; Levinson, Amanda; Feng, Tianshu; Marcus, Sue M; Vermes, Donna; Flood, Pamela; Simpson, Helen B (2013). “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept”. Neuropsychopharmacology 38 (12): 2475–2483. doi:10.1038/npp.2013.150. PMC 3799067. PMID 23783065.
Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE (2018). “Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review”. Front Psychiatry: 277. doi:10.3389/fpsyt.2018.00277. PMC 6094990. PMID 30140240.

nimh.nih.gov

Thomas Insel (2014年10月1日). “Director’s Blog: Ketamine”. National Institute of Mental Health (NIMH). 2015年11月1日閲覧。

nikkei.com

藤井寛子 (2017年6月7日). “麻酔薬ケタミン、抗うつ薬へ研究～即効性が強み”. 日本経済新聞 2018年2月1日閲覧。

oxfordjournals.org

bja.oxfordjournals.org

Hirota K, et al. (1996-10). “Ketamine: Its mechanism(s) of action and unusual clinical uses”. en:British Journal of Anaesthesia. 77 (4): 441-4. doi:10.1093/bja/77.4.441. PMID 8942324.

pharmaceutical-journal.com

Janna Lawrence (2015年3月). “The Secret Life of ketamine”. 2020年1月24日閲覧。

reftag.appspot.com

Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE (2018). “Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review”. Front Psychiatry: 277. doi:10.3389/fpsyt.2018.00277. PMC 6094990. PMID 30140240.

roche.com

“Roche – Pipeline” (2015年). 2015年5月1日時点のオリジナルよりアーカイブ。2015年5月14日閲覧。

saitama-np.co.jp

“各国発、埼玉経由で…違法薬物輸入の男を再逮捕”. 埼玉新聞 (2023年7月6日). 2023年10月31日閲覧。

scienceblog.co.uk

scienceblog (2022年8月23日). “うつ病のケタミン治療 - scienceblog”. サイエンスブログ. 2023年1月26日閲覧。

slam.nhs.uk

“Ketamine Update”. South London and Maudsley NHS Foundation Trust (14 of May 2014). 2015年11月1日閲覧。

springer.com

adisinsight.springer.com

“Esketamine - Johnson & Johnson - AdisInsight”. 2017年11月7日閲覧。

thelancet.com

“Side-effects associated with ketamine use in depression: a systematic review”. Lancet Psychiatry 5 (1): 65–78. (2018). doi:10.1016/S2215-0366(17)30272-9. PMID 28757132.

web.archive.org

“Roche – Pipeline” (2015年). 2015年5月1日時点のオリジナルよりアーカイブ。2015年5月14日閲覧。

wikipedia.org

en.wikipedia.org